title: Effects of heparin and aminoguanidine on glomerular basement membrane thickening in diabetic rats.
abstract: The effects of heparin and aminoguanidine on glomerular basement membrane thickening were studied in streptozotocin diabetic Sprague-Dawley rats. A placebo-treated group and a non-diabetic group served as controls. All diabetic rats remained severely hyperglycaemic (23 mmol/l) throughout the 8-month study period. At the end of this time relative kidney weight was significantly increased in diabetic control rats (4.9 +/- 0.5 g/kg b.w.) compared with non-diabetic rats (3.3 +/- 0.3 g/kg). This increase was not affected by the intervention treatments. Glomerular basement membrane thickness increased 32% in diabetic control rats (240 +/- 24 nm) compared with non-diabetic rats (182 +/- 20 nm). This increase was prevented by s.c. treatment with both unfractionated and low molecular weight heparins, while basement membrane thickness was the same in animals treated with oral heparins and aminoguanidine and untreated diabetic rats. Macroscopic malignant kidney tumours were seen in three aminoguanidine-treated rats. In conclusion, subcutaneously administered heparin prevents diabetes-induced glomerular basement membrane thickening.
authors.affiliation: Steno Diabetes Center, Gentofte, Denmark.
authors.forename: P S
authors.initials: PS
authors.lastname: Oturai
authors.forename: R
authors.initials: R
authors.lastname: Rasch
authors.forename: E
authors.initials: E
authors.lastname: Hasselager
authors.forename: P B
authors.initials: PB
authors.lastname: Johansen
authors.forename: H
authors.initials: H
authors.lastname: Yokoyama
authors.forename: M K
authors.initials: MK
authors.lastname: Thomsen
authors.forename: B
authors.initials: B
authors.lastname: Myrup
authors.forename: A
authors.initials: A
authors.lastname: Kofoed-Enevoldsen
authors.forename: T
authors.initials: T
authors.lastname: Deckert
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001485:Basement Membrane / Q000187:drug effects / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000473:pathology*; D003928:Diabetic Nephropathies / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D006146:Guanidines / Q000627:therapeutic use*; D006493:Heparin / Q000627:therapeutic use*; D006984:Hypertrophy; D007279:Injections, Subcutaneous; D007678:Kidney Glomerulus / Q000187:drug effects* / Q000473:pathology*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin
chemical_list: D006146:Guanidines; D013311:Streptozocin; D006493:Heparin; C004479:pimagedine